William Blair analyst Myles Minter has reiterated their bullish stance on LRMR stock, giving a Buy rating on March 3.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors related to Larimar’s lead asset, nomlabofusp, and its regulatory trajectory in Friedreich’s ataxia. He believes the drug is positioned to become the first disease‑modifying frataxin replacement therapy, and argues that Larimar’s equity value does not yet reflect this potential, especially when compared with the high price Biogen paid for Reata’s Skyclarys, which offers more limited long‑term disease control.
Minter also highlights a favorable regulatory backdrop, citing the FDA’s breakthrough therapy designation, agreement on a June 2026 accelerated BLA filing, acceptance of skin frataxin as a surrogate endpoint, and comfort with using FA‑COMS natural history data as an external control. While he acknowledges ongoing concerns around anaphylaxis and regulatory risk, he views protocol changes and upcoming Phase II data as de‑risking catalysts and sees 2026 as a key inflection year with a robust risk/reward profile supporting his Buy stance.
According to TipRanks, Minter is a top 100 analyst with an average return of 34.2% and a 60.42% success rate. Minter covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Immunic, and Intellia Therapeutics.
In another report released on March 3, Wedbush also maintained a Buy rating on the stock with a $12.00 price target.